Welcome to our dedicated page for AMAR news (Ticker: AMAR), a resource for investors and traders seeking the latest updates and insights on AMAR stock.
This page contains historical news coverage for Ainos Inc (AMAR), which operated as a pharmaceutical preparation manufacturing company. The company has since undergone a corporate transformation, changing its name from Amarillo Biosciences Inc to Ainos Inc and transitioning to the AIMD ticker symbol on NASDAQ. This archive provides context on the company's history and the developments that occurred under the AMAR ticker.
During its operations under the AMAR symbol, the company focused on developing biologics for human and animal diseases, with particular emphasis on low-dose interferon drug solutions. News coverage from this period includes announcements related to product development partnerships, corporate restructuring events, and strategic initiatives in the pharmaceutical and medical technology sectors. The company's evolution from a traditional pharmaceutical manufacturer to a medical technology company integrating AI-powered devices represents a significant strategic pivot documented in these historical news items.
Investors seeking current news and developments should reference the AIMD ticker symbol, which reflects the company's current trading designation. The historical AMAR news archive documents the company's earlier phase under the Amarillo Biosciences name and provides valuable context for understanding the company's transformation journey. Browse this archive to understand the corporate changes, business developments, and strategic decisions that shaped the company's evolution from its original pharmaceutical focus to its current operations.
Ainos, Inc. (OTC PINK:AIMD) has signed an exclusive agreement with Taiwan Carbon Nano Corporation (TCNT) to act as the master sales and marketing agent for the Ainos SARS-CoV-2 Antigen Rapid Test Kit in Taiwan.
Following the emergency use authorization from the Taiwan Food and Drug Administration on June 7, Ainos aims to promote the kit regionally. The test provides results in 15 minutes with high sensitivity and specificity, featuring a unique smartphone tracking function.
Ainos, Inc. (formerly Amarillo Biosciences) announced on May 24, 2021, that the Financial Industry Regulatory Authority (FINRA) approved its name change and new ticker symbol AIMD. This change takes effect immediately, following a securities purchase transaction with Ainos, Inc. of the Cayman Islands. The company has engaged Donohoe Advisory Associates LLC to help evaluate U.S. National Securities Exchanges listing requirements. Ainos focuses on developing innovative healthcare products, including diagnostics for COVID-19 and other infections.
Ainos, Inc. (OTCBB:AMAR), formerly Amarillo Biosciences, Inc., has finalized a Securities Purchase Agreement with strategic investor Ainos, Inc. (Cayman Islands). The Company issued 100 million shares at $0.20 per share in exchange for patent assignments, expanding its authorized stock to 300 million shares. Following the transaction, Ainos KY owns approximately 70.39% of the Company’s outstanding shares. The new leadership aims to enhance the Company’s diagnostic capabilities, focusing on rapid test kits for various diseases, including COVID-19.
